cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alx Oncology Holdings Inc
2 own
1 watching
Current Price
$6.81
$0.3
(4.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
278.27M
52-Week High
52-Week High
15.39
52-Week Low
52-Week Low
4.23
Average Volume
Average Volume
0.21M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization278.27M
icon52-Week High15.39
icon52-Week Low4.23
iconAverage Volume0.21M
iconDividend Yield--
iconP/E Ratio--
What does the Alx Oncology Holdings Inc do?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin s lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Read More
How much money does Alx Oncology Holdings Inc make?
News & Events about Alx Oncology Holdings Inc.
Globe Newswire
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted key milestones anticipated...
Globe Newswire
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive...
Globe Newswire
5 months ago
-- Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML-- No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax -- ALX Oncology to Host Conference Call on December 13th at 7:30...
Globe Newswire
6 months ago
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the Company will be presenting clinical data from the dose ...
Globe Newswire
7 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (ALX Oncology) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Progress abstracts related ...
Frequently Asked Questions
Frequently Asked Questions
What is Alx Oncology Holdings Inc share price today?
plus_minus_icon
Can Indians buy Alx Oncology Holdings Inc shares?
plus_minus_icon
How can I buy Alx Oncology Holdings Inc shares from India?
plus_minus_icon
Can Fractional shares of Alx Oncology Holdings Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Alx Oncology Holdings Inc stocks?
plus_minus_icon
What is today’s traded volume of Alx Oncology Holdings Inc?
plus_minus_icon
What is today’s market capitalisation of Alx Oncology Holdings Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Alx Oncology Holdings Inc?
plus_minus_icon
What percentage is Alx Oncology Holdings Inc down from its 52-Week High?
plus_minus_icon
What percentage is Alx Oncology Holdings Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$6.81
$0.3
(4.61%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$5.75
$-0.11 (-1.88 %)
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$4.90
$-0.16 (-3.16 %)
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.35
$0.03 (0.47 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.92
$-0.08 (-1.33 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
VERRICA PHARMACEUTICALS INC
VERRICA PHARMACEUTICALS INC
$5.75
$-0.11 (-1.88 %)
SUTRO BIOPHARMA INC
SUTRO BIOPHARMA INC
$4.90
$-0.16 (-3.16 %)
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$6.35
$0.03 (0.47 %)
INOZYME PHARMA INC
INOZYME PHARMA INC
$5.92
$-0.08 (-1.33 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00